Drugs / SAFOTIBANT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01319487 | May 2011 → Mar 2012 | diabetic macular edema | Fovea Pharmaceuticals SA | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAFOTIBANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL1254771 ↗ |
| Known as | FOV-2304 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1254771 ↗ |
| Known as | FOV2304 | “Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated...” NCT01319487 ↗ |
| Known as | LF22-0542 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1254771 ↗ |
| Known as | Safotibant phosphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1254771 ↗ |
| Action | Inhibit | “Bradykinin B1 receptor antagonist” CHEMBL1254771 ↗ |
| Modality | Small molecule | — CHEMBL1254771 ↗ |
| Route | Topical | “Topical Administration of FOV2304 (High Dose or Low Dose)” NCT01319487 ↗ |
| Target | BDKRB1 | “Bradykinin B1 receptor antagonist” CHEMBL1254771 ↗ |